Related Experiment Video

Updated: Jul 14, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Pediatric quality of life in transitioning to the insulin pump: does prior regimen make a difference?

Fran R Cogen1, Celia Henderson, Jennifer A Hansen

  • 1Division of Endocrinology and Diabetes, Department of Pediatrics, Washington, District of Columbia, USA.

Clinical Pediatrics
|June 23, 2007
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) improved quality of life for children with diabetes transitioning from conventional therapy. Benefits were sustained at six months, highlighting CSII as a key consideration for pediatric diabetes management.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Quality of Life Research

Background:

  • Diabetes management has evolved from conventional methods to intensive regimens like multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII).
  • CSII represents the most intensive form of diabetes management, requiring careful consideration of lifestyle and quality-of-life factors beyond medical benefits before adoption.

Purpose of the Study:

  • To assess short-term and long-term changes in quality of life for children transitioning to CSII.
  • To compare the impact of CSII initiation on quality of life based on the pre-CSII diabetes regimen (conventional vs. MDI).

Main Methods:

  • A study involving 52 children with diabetes was conducted before their transition to CSII.
  • Quality of life was evaluated based on the children's previous diabetes management regimen (conventional or MDI).

Main Results:

  • Significant improvements in quality of life were observed exclusively in children transitioning to CSII from conventional therapy.
  • These quality-of-life improvements were maintained for at least six months after initiating CSII therapy.
  • CSII devices did not universally enhance satisfaction with diabetes control across all pediatric patients.

Conclusions:

  • Quality of life is a critical factor for children transitioning to intensive diabetes management regimens.
  • The decision to transition to CSII should involve a thorough discussion of the risks and benefits of both intensive regimens.
  • CSII may not be associated with improved diabetes control satisfaction for all pediatric individuals.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...